Publications by authors named "Laperche S"
Article Synopsis
- Hepatitis B core antibody (anti-HBc) screening is used in blood establishments worldwide to help prevent the transmission of hepatitis B virus (HBV), especially from donors with occult HBV infection (OBI).
- A survey conducted revealed varied practices in HBV screening across 30 responses from 25 countries, with some establishments screening all donations for anti-HBc and HBV DNA, while others had different approaches, leading to inconsistencies in donor deferral strategies.
- The findings highlight the need for improved confirmation of anti-HBc results to minimize unnecessary donor deferrals while balancing the risk of transmission from anti-HBc negative OBI donors, particularly in high-endemic regions where sensitive HBV DNA testing is crucial.
Background And Objectives: In 2016, France allowed men who have sex with men (MSM) to donate blood if they had not had sex with men in the previous 12 months. In April 2020, this restriction was relaxed to 4 months due to the lack of negative impact observed on blood safety. This study assesses the impact of reducing this deferral period on epidemiological surveillance indicators.
View Article and Find Full Text PDFArticle Synopsis
- Syphilis cases among blood donors in France have been rising, with a significant uptick observed in 2022 compared to earlier years.
- Data from over 45 million donations (2007-2022) revealed that the infection rate was notably higher in males, particularly among men who have sex with men (MSM), whose risk factor percentage increased over time.
- A non-treponemic test (NTT) was used to assess infection recency, but the data were insufficient to reliably differentiate between recent and past infections among the syphilis-positive donors.
Background: The large dengue (DENV) and chikungunya (CHIKV) outbreaks observed during the last decade across the world, as well as local transmissions in non-endemic areas are a growing concern for blood safety. The aim of this study was to evaluate and compare the sensitivity of nucleic acid tests (NAT) detecting DENV and CHIKV RNA.
Materials And Methods: Using DENV 1 to 4 International Standards, the limits of detection (LODs) calculated by probit analysis of two NAT assays; the cobas CHIKV/DENV assay (Roche Diagnostics) and the Procleix Dengue Virus Assay (Grifols) were compared.
In France, blood donations are tested in pools of 96 samples for parvovirus B19 (B19V) DNA to discard plasma for fractionation when it contains high viral loads. Between January 2015 and March 2024, B19V-positive donations decreased during the COVID-19 pandemic, followed by a strong rebound in 2023 and unusually high circulation during winter 2023/24 (ca 10 times higher December 2023-March 2024 vs the pre-pandemic period). Variations over time are probably related to measures implemented to limit SARS-CoV-2 spread.
View Article and Find Full Text PDFArticle Synopsis
- Nucleic acid-amplification testing (NAT) is a method used to check blood donations for harmful viruses to keep people safe.
- In 2019, a global survey showed that countries mostly followed government rules for testing blood for viruses like HIV and hepatitis.
- The results indicated a trend towards using individual samples for testing instead of larger pools to improve safety in blood donations.
Article Synopsis
- The project reviewed the global use of nucleic acid amplification testing (NAT) in blood services to detect viral and parasite nucleic acids and reduce transfusion-related infections.
- A survey conducted among members of the International Society of Blood Transfusion revealed a significant increase in NAT adoption over the past decade, with data showing low but notable positivity rates for various viruses in blood donations.
- While NAT has enhanced blood transfusion safety worldwide, there is a call to address economic barriers that prevent some regions from implementing these important testing methods.
Background And Objectives: Pathogen reduction (PR) technology may reduce the risk of transfusion-transmitted infections (TTIs), notably transfusion-transmitted bacterial infection (TTBI) associated with platelet concentrates (PCs). PR (amotosalen/UVA treatment) was implemented for all PCs transfused in France in November 2017. No bacterial detection was in place beforehand.
View Article and Find Full Text PDFBackground And Objectives: Data from 21 years (2000-2020) of haemovigilance were used to assess human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV) incidence rates in repeat blood donors and the occurrence of transfusion-transmitted (TT) viral infections.
Materials And Methods: Blood donors who converted for HIV, HCV or HBV markers within serial three-year analysis periods were included. Epidemiological and virological data were retrieved from the national epidemiological donor database and were supplemented with information on blood components and the infection status of recipients of the previous negative donation (D.
Background And Objectives: Since the advent of AIDS, men who have sex with men (MSM) have often been deferred from blood donation. In France, quarantine plasma donation by MSM donors with the same deferral rules as for other donors was introduced in July 2016 and continued up to March 2022. At this time, MSM-specific deferral criteria were lifted for all blood or plasma donation.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to evaluate the connection between the concentration of anti-HBs antibodies and their ability to neutralize the hepatitis B virus, revealing that higher antibody levels do not always correspond to better neutralization effectiveness.
- It involved comparing IgG antibodies from individuals who received different types of hepatitis B vaccines or recovered from infection and testing their neutralization activity in vitro.
- The findings suggest that measuring anti-HBs levels alone is inadequate for assessing neutralization, recommending the inclusion of neutralization assays in quality control and highlighting the importance of matching vaccine types with circulating HBV strains.
Article Synopsis
- Hepatitis B virus (HBV) is the most common viral infection found in blood donors in France, with a significant majority (98%) of HBV-positive cases from first-time donors between 2000 and 2020.
- Over two decades, there was a notable decrease in both HBV prevalence (2.8-fold) and the risk of transfusion-transmitted HBV infections (13-fold), primarily attributed to the screening processes and the origins of donors.
- The main risk factor for HBV infection was donors from endemic countries (66.5%), with genotype D being the most prevalent among positive cases, while a robust screening strategy ensures high levels of blood safety.
Background And Objectives: The risk of a blood donation contaminated with hepatitis E virus (HEV) entering the blood supply before introducing universal HEV-RNA screening in France was estimated to assess the benefit of such a measure.
Materials And Methods: The results of selective HEV nucleic acid testing (HEV-NAT) performed in mini pool of six plasma donations between 2018 and 2020 were extrapolated to the whole blood donor (BD) population after adjustment on three variables: regional establishment, sex and age group.
Results: Among the 246,285 plasma donations collected from 172,635 BDs tested for HEV-RNA, 248 (10.
Hepatitis B virus (HBV) morphogenesis is characterized by a large over-production of subviral particles and recently described new forms in parallel of complete viral particles (VP). This study was designed to depict circulating viral forms in HBV infected patient plasmas, using velocity gradients and most sensitive viral markers. Plasmas from chronic hepatitis B (CHB) patients, HBeAg positive or negative, genotype D or E, were fractionated on velocity and equilibrium gradients with or without detergent treatment.
View Article and Find Full Text PDFBackground: The diagnostic accuracy of the Elecsys® HCV Duo antigen-antibody combination immunoassay (Roche Diagnostics GmbH) was evaluated for the detection of hepatitis C virus (HCV) infection, versus commercially available comparators.
Methods: This multicenter study (August 2020-March 2021) assessed the specificity of the Elecsys HCV Duo immunoassay and comparator assays in blood donor and routine clinical laboratory samples; sensitivity was determined in confirmed HCV-positive samples and seroconversion panels. The Elecsys HCV Duo immunoassay was compared with the Monolisa HCV Ag-Ab ULTRA V2, Murex HCV Ag/Ab Combination and ARCHITECT HCV Ag assays, as well as nucleic acid testing (NAT).
Background: The French health authorities are considering expanding the current selective hepatitis E virus (HEV)-RNA testing procedure to include all donations in order to further reduce transfusion-transmitted HEV infection. Data obtained from blood donors (BDs) tested for HEV-RNA between 2015 and 2021 were used to assess the most efficient nucleic acid testing (NAT) strategy.
Materials And Methods: Viral loads (VLs) and the plasma volume of blood components, as well as an HEV-RNA dose of 3.
Absence of anti-HBc reactivity with detectable anti-HBs was observed in blood donors with occult hepatitis B virus (HBV) infection (OBI). The prevalence and mechanisms underlying this uncommon condition were investigated over time in Chinese blood donors with OBI. Isolated anti-HBs OBI status was identified from 466,911 donors from Dalian, China, and monitored in follow-up (range: 2.
View Article and Find Full Text PDFObjective: This study compared two assays aimed at confirming the presence of anti-HCV antibodies (Ab) after a positive screening: Geenius HCV supplemental assay (Bio-Rad, Marne la Coquette, France) and the Inno-LIA HCV score assay (Fujirebio, Les Ulis, France).
Material And Methods: A total of 180 archived samples were investigated including 119 samples collected at different stages of HCV infection in 25 hemodialyzed patients who underwent HCV seroconversion, 14 samples from 4 commercial seroconversion panels, 47 Ab positive/HCV-RNA positive blood donations of which 7 showing an single reactivity in confirmatory assays. Samples were investigated and results were interpreted with the two assays according to the manufacturers' instructions.
Background And Objective: The SARS-CoV-2 Omicron variant displays increased infectiveness as well as mutations resulting in reduced neutralizing activity of antibodies acquired after vaccination or infection involving earlier strains. To assess the ability of vaccinated COVID-19 convalescent plasma (CCP-V) collected before November 2021 to seroneutralize Omicron, we compared neutralizing antibody (nAb) titres of 63 samples against Omicron and earlier B.1 (D614G) strains.
View Article and Find Full Text PDFBackground: There is growing evidence to support the hypothesis that SARS-CoV-2 is probably not transmissible by blood transfusion. In this study, we use the data gathered over one year by the French haemovigilance network on post-donation information related to SARS-CoV-2, and virological investigations on corresponding plasma to explore viral transmission by transfusion.
Materials And Methods: Whenever a donor reported COVID-19 symptoms and/or a positive SARS-CoV-2 nasopharyngeal (NP) PCR test, information regarding diagnosis and symptoms was collected using a specific questionnaire, and repository plasmas were screened using the SARS-COV-2 R-GENE assay (Biomérieux).
Background: To investigate the transmission of SARS-CoV-2 via blood, we conducted retrospective molecular screening in blood donated during the first pandemic peak in the two French regions with the highest community transmission.
Methods: Archived plasma samples randomly selected from donations collected between March 23 and 29, 2020, in Eastern and Northern regions of France were tested for SARS-CoV-2 RNA in minipools of 4 donations (MP4) using the Grifols ProcleixSARS-CoV-2 assay. Reactive MP4 and the four corresponding plasmas were further tested with alternative RT-PCRs and sequencing.
Background: Anti-hepatitis A virus (HAV) antibody titers at 20 IU/L are assumed to correlate with protection against HAV challenge.
Methods: We examined the accuracy and precision of currently in use immunoassays for total or anti-HAV IgG determination, by repeated testing of dilutions of the international anti-HAV standard, within a 10-50 IU/mL concentration range.
Results And Conclusion: Eight immunoassays were evaluated.